eFFECTOR Therapeutics, Inc. Common Stock
EFTR
EFTR was delisted on the 2nd of July, 2024.
24 hedge funds and large institutions have $33.9M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 2 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
26% more funds holding
Funds holding: 19 → 24 (+5)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
62% less capital invested
Capital invested by funds: $89.7M → $33.9M (-$55.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Parallel Advisors
San Francisco,
California
|
+$2.46M |
| 2 |
ECM
Evolution Capital Management
Crystal Bay,
Nevada
|
+$1.28M |
| 3 |
RF
Resolute Financial
Newburyport,
Massachusetts
|
+$72.6K |
| 4 |
Renaissance Technologies
New York
|
+$70.9K |
| 5 |
CC
Callan Capital
La Jolla,
California
|
+$48.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
ALPS Advisors
Denver,
Colorado
|
-$187K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$242 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Simplex Trading
Chicago,
Illinois
| – | +$363 | +6 | New |
|
EFTR Hedge Fund Activity: Q2 2022 in Review
24 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q2 2022, worth a combined $33.9M — down 62% from $89.7M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new EFTR positions and 2 closed out — a net gain of 5 holders — while 8 added to existing stakes and 1 trimmed.
The largest buyer was Parallel Advisors, adding an estimated $2.46M. The largest seller was ALPS Advisors, exiting entirely with an estimated $187K sold.
- 24 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q2 2022, up from 19 in Q1 2022.
- Funds reported $33.9M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q2 2022, down 62% quarter-over-quarter.
- 7 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q2 2022 and 2 closed out, a net change of +5 holders.
- The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q2 2022 was Parallel Advisors, an estimated $2.46M added.
- The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q2 2022 was ALPS Advisors, an estimated $187K sold.
Based on aggregated 13F filings for Q2 2022.